Format
Sort by
Items per page

Send to

Choose Destination

Best matches for breast neoplasm screening AND chemoprevention AND malignant neoplasm of breast AND woman:

Search results

Items: 1 to 20 of 237

1.

Precancer Atlas to Drive Precision Prevention Trials.

Spira A, Yurgelun MB, Alexandrov L, Rao A, Bejar R, Polyak K, Giannakis M, Shilatifard A, Finn OJ, Dhodapkar M, Kay NE, Braggio E, Vilar E, Mazzilli SA, Rebbeck TR, Garber JE, Velculescu VE, Disis ML, Wallace DC, Lippman SM.

Cancer Res. 2017 Apr 1;77(7):1510-1541. doi: 10.1158/0008-5472.CAN-16-2346.

PMID:
28373404
2.

Breast cancer prevention strategies in lobular carcinoma in situ: A decision analysis.

Wong SM, Stout NK, Punglia RS, Prakash I, Sagara Y, Golshan M.

Cancer. 2017 Jul 15;123(14):2609-2617. doi: 10.1002/cncr.30644. Epub 2017 Feb 21.

PMID:
28221673
3.

BRCA mutation genetic testing implications in the United States.

Bayraktar S, Arun B.

Breast. 2017 Feb;31:224-232. doi: 10.1016/j.breast.2016.11.021. Epub 2016 Dec 6. Review.

PMID:
27931006
4.

Prevention of breast cancer.

Olver IN.

Med J Aust. 2016 Nov 21;205(10):475-479. Review.

PMID:
27852187
5.

Initiation of and adherence to tamoxifen and aromatase inhibitor therapy among elderly women with ductal carcinoma in situ.

Zhao H, Hei N, Wu Y, Chan W, Lei X, Cameron C, Chang S, Chavez-MacGregor M, Giordano SH.

Cancer. 2017 May 15;123(6):940-947. doi: 10.1002/cncr.30425. Epub 2016 Oct 25.

PMID:
27780311
6.
7.

Management of women with a hereditary predisposition for breast cancer.

Jatoi I, Benson JR.

Future Oncol. 2016 Oct;12(19):2277-88. doi: 10.2217/fon-2016-0186. Epub 2016 Jul 7. Review.

PMID:
27384952
8.

Circulating insulin-like growth factor-I, insulin-like growth factor binding protein-3 and terminal duct lobular unit involution of the breast: a cross-sectional study of women with benign breast disease.

Horne HN, Sherman ME, Pfeiffer RM, Figueroa JD, Khodr ZG, Falk RT, Pollak M, Patel DA, Palakal MM, Linville L, Papathomas D, Geller B, Vacek PM, Weaver DL, Chicoine R, Shepherd J, Mahmoudzadeh AP, Wang J, Fan B, Malkov S, Herschorn S, Hewitt SM, Brinton LA, Gierach GL.

Breast Cancer Res. 2016 Feb 18;18(1):24. doi: 10.1186/s13058-016-0678-4.

9.

[Hormonotherapy for breast cancer prevention: What about women with genetic predisposition to breast cancer?].

Sénéchal C, Reyal F, Callet N, This P, Noguès C, Stoppa-Lyonnet D, Fourme E.

Bull Cancer. 2016 Mar;103(3):273-81. doi: 10.1016/j.bulcan.2016.01.001. Epub 2016 Feb 3. Review. French.

PMID:
26852151
10.

Genetic testing for hereditary cancer predisposition: BRCA1/2, Lynch syndrome, and beyond.

Hall MJ, Obeid EI, Schwartz SC, Mantia-Smaldone G, Forman AD, Daly MB.

Gynecol Oncol. 2016 Mar;140(3):565-74. doi: 10.1016/j.ygyno.2016.01.019. Epub 2016 Jan 23. Review.

11.

Factors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta-analysis.

Smith SG, Sestak I, Forster A, Partridge A, Side L, Wolf MS, Horne R, Wardle J, Cuzick J.

Ann Oncol. 2016 Apr;27(4):575-90. doi: 10.1093/annonc/mdv590. Epub 2015 Dec 8. Review.

12.

Lobular Carcinoma in Situ: A 29-Year Longitudinal Experience Evaluating Clinicopathologic Features and Breast Cancer Risk.

King TA, Pilewskie M, Muhsen S, Patil S, Mautner SK, Park A, Oskar S, Guerini-Rocco E, Boafo C, Gooch JC, De Brot M, Reis-Filho JS, Morrogh M, Andrade VP, Sakr RA, Morrow M.

J Clin Oncol. 2015 Nov 20;33(33):3945-52. doi: 10.1200/JCO.2015.61.4743. Epub 2015 Sep 14.

13.

Is Excisional Biopsy and Chemoprevention Warranted in Patients With Atypical Lobular Hyperplasia on Core Biopsy?

Allen S, Levine EA, Lesko N, Howard-Mcnatt M.

Am Surg. 2015 Sep;81(9):876-8.

PMID:
26350664
14.

Gaining control over breast cancer risk: Transforming vulnerability, uncertainty, and the future through clinical trial participation - a qualitative study.

Holmberg C, Whitehouse K, Daly M, McCaskill-Stevens W.

Sociol Health Illn. 2015 Nov;37(8):1373-87. doi: 10.1111/1467-9566.12307. Epub 2015 Aug 3.

15.

Why Breast Cancer Risk by the Numbers Is Not Enough: Evaluation of a Decision Aid in Multi-Ethnic, Low-Numerate Women.

Kukafka R, Yi H, Xiao T, Thomas P, Aguirre A, Smalletz C, David R, Crew K.

J Med Internet Res. 2015 Jul 14;17(7):e165. doi: 10.2196/jmir.4028.

16.

Adherence to WCRF/AICR cancer prevention recommendations and metabolic syndrome in breast cancer patients.

Bruno E, Gargano G, Villarini A, Traina A, Johansson H, Mano MP, Santucci De Magistris M, Simeoni M, Consolaro E, Mercandino A, Barbero M, Galasso R, Bassi MC, Zarcone M, Zagallo E, Venturelli E, Bellegotti M, Berrino F, Pasanisi P.

Int J Cancer. 2016 Jan 1;138(1):237-44. doi: 10.1002/ijc.29689. Epub 2015 Jul 28.

17.

Breast Cancer Risk Assessment Among Low-Income Women of Color in Primary Care: A Pilot Study.

Anderson EE, Tejeda S, Childers K, Stolley MR, Warnecke RB, Hoskins KF.

J Oncol Pract. 2015 Jul;11(4):e460-7. doi: 10.1200/JOP.2014.003558. Epub 2015 Jun 2.

18.

Can diet and lifestyle prevent breast cancer: what is the evidence?

Harvie M, Howell A, Evans DG.

Am Soc Clin Oncol Educ Book. 2015:e66-73. doi: 10.14694/EdBook_AM.2015.35.e66. Review.

19.

Practical problems with clinical guidelines for breast cancer prevention based on remaining lifetime risk.

Quante AS, Whittemore AS, Shriver T, Hopper JL, Strauch K, Terry MB.

J Natl Cancer Inst. 2015 May 8;107(7). pii: djv124. doi: 10.1093/jnci/djv124. Print 2015 Jul.

20.

Gene analysis techniques and susceptibility gene discovery in non-BRCA1/BRCA2 familial breast cancer.

Aloraifi F, Boland MR, Green AJ, Geraghty JG.

Surg Oncol. 2015 Jun;24(2):100-9. doi: 10.1016/j.suronc.2015.04.003. Epub 2015 Apr 13. Review.

PMID:
25936246

Supplemental Content

Loading ...
Support Center